Nuvasive Inc (NUVA)

HEALTH CARE: HEALTH CARE SUPPLIES
SIC: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

7475 LUSK BLVD. SAN DIEGO, CA 92121

Focuses on the design, development and marketing of products for the surgical treatment of spine disorders. The company's principal products include a minimally invasive surgical platform, maximum access surgery (MAS) and classic fusion products.

Data as of 2020-07-04
Market Cap2.925 Billion Shares Outstanding51.248 Million Avg 30-day Volume1.031 Million
P/E Ratio48.9 Dividend Yield EPS1.16
Price/Sales3.397 Price cash flow ratio14.1 Price free cash flow ratio49.9
Book Value17.29 Price to Tangible Book21.43 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.35272
BETA1.36999 52-week High/Low81.91 / 28.55 Stddev0.098233
View SEC Filings from NUVA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 2 (0.13%)
13F Filers holding this stock: 260 68 (4.45%)
Aggregate 13F shares on 03/31/2020: 52.03 Million 20.326 Million
Aggregate 13F shares on 12/31/2019: 54.215 Million 21.074 Million
Percent change: -4.03% -3.55%
Funds creating new positions: 41 18
Funds Adding to an existing position: 81 16
Funds closing out their position: 60 25
Funds reducing their position: 101 32
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NUVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NUVA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

3 Thousand total shares from 1 transactions

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

VALENTINE KEITH CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
279,807 2020-06-30 0

LIPSCHULTZ TYLER SVP, ORTHOBIOLOGICS AND BD

  • Officer
95,822 2020-06-30 0

ROSENBERG DONALD J EVP & GENERAL COUNSEL

  • Officer
12,802 2020-06-29 1

CAPPS VICKIE L

  • Director
0 2020-06-23 1

FARRELL PETER C

  • Director
0 2020-06-22 0

RYDIN JEFFREY P

  • Director
414,888 2020-06-17 0

NORWALK LESLIE V

  • Director
4,909 2020-06-17 1

BLACKFORD QUENTIN S.

  • Director
530,180 2020-06-17 0

HUENNEKENS R SCOTT

  • Director
99,670 2020-06-15 1

HANNON JASON

  • Director
0 2020-06-08 0

LUKIANOV ALEXIS V

  • Director
16,083 2020-06-08 0

LINK MATTHEW PRESIDENT

  • Officer
82,595 2020-06-08 4

PAOLUCCI MICHAEL E

  • Director
19,779 2020-06-08 0

OBOYLE KEVIN C

  • Director
100,802 2020-06-05 0

LUCIER GREGORY T

  • Director
0 2020-05-28 3

WOLTERMAN DAN

  • Director
0 2020-05-28 1

FRIEL ROBERT F

  • Director
0 2020-05-28 1

DEFORD JOHN A

  • Director
0 2020-05-28 1

STAFSLIEN JOAN

  • Director
25,000 2020-04-27 0

HUNSAKER CRAIG E EVP, PEOPLE/CULTURE & GC

  • Officer
1,048,092 2020-04-22 0

MILES PATRICK CEO

  • Officer
  • Director
5,315,749 2020-04-22 0

SYLVAIN JEREME M SVP, FINANCE & CAO

  • Officer
13,417 2020-03-11 0

BARRY JAMES CHRISTOPHER CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-03-02 2

HARBAUGH MATTHEW K EVP AND CFO

  • Officer
0 2020-03-02 3

WOLF DALE A. SVP, GLOBAL OPERATIONS

  • Officer
0 2020-03-02 2

SISITSKY NATHANIEL SVP & GENERAL COUNSEL

  • Officer
10,348 2020-03-01 1

VITALE LUCAS CHIEF HUMAN RESOURCES OFFICER

  • Officer
6,850 2020-03-01 1

MCCLINTOCK PAUL PRESIDENT, U.S. COMMERCIAL

  • Officer
400 2019-11-11 1

HOWE LESLEY H

19,397 2019-08-06 0

OHALLERAN MICHAEL D

  • Director
0 2019-05-09 0

ASARPOTA RAJESH CFO

  • Officer
0 2019-03-01 0

LEDDY PETER MICHAEL

  • FORMER EVP, PEOPLE AND CULTURE
0 2018-12-31 0

CAROL COX

  • FORMER EVP EXTERNAL AFFAIRS
0 2018-12-31 0

ROZOW STEPHEN EVP, GLOBAL PROCESS

  • Officer
4,075 2018-05-01 0

KIIL HARRY SKIP EVP INTERNATIONAL

  • Officer
0 2017-06-01 0

ROSCHAK EDMUND J CEO, NUVASIVE SPEC. ORTHOPEDIC

  • Officer
0 2017-02-08 0

BLAIR JACK R

  • Director
No longer subject to file 2016-05-19 0

HANSON JASON DAVID EVP, STRATEGY, CORP DEV & GC

  • Officer
500 2015-11-30 0

POWERS RUSSELL EVP

  • Officer
64,201 2015-10-01 0

MORE EILEEN M

  • Director
16,833 2014-11-13 0

LAMBERT MICHAEL EVP & CFO

  • Officer
13,631 2014-08-01 0

HUNT ROBERT J

  • Director
34,500 2014-05-05 0

TREHARNE RICHARD III

  • Director
7,000 2013-08-06 0

YUAN HANSEN A

  • Director
0 2009-06-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

LINK MATTHEW - Officer PRESIDENT

2020-06-08 S 3,000 $67.00 d 82,595 82,595.00 direct

DEFORD JOHN A - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

HUENNEKENS R SCOTT - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

ROSENBERG DONALD J - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

WOLTERMAN DAN - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

LUCIER GREGORY T - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

CAPPS VICKIE L - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

FRIEL ROBERT F - Director

2020-05-28 A 3,095 a 3,095 0.00 direct

NORWALK LESLIE V - Director

2020-05-28 A 3,095 a 3,095 0.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments